Studies on the Immunomodulatory Effects of Lactoferrin in Rats Infected with E. coli


Eighty male albino rats of Westar strain (350 ± 10 g), 10 to 12 weeks old were divided into four groups. The groups treated are as following. The first control group (Gp. I) was given intraperitoneally in normal saline (1 mL). The second group (Gp. II) was orally infected with 3 × 1012 CFU of E. coli /Kg. BW. The third group (Gp. III) was infected with E. coli and treated with (0.5%) lactoferrin (LF) 72 hours before E. coli infection in filtered tap water for the duration of the experiment (21 days). The fourth group (Gp. IV) was administrated with LF only (0.5%) in drinking water. Two separate blood samples were collected from heart puncture at the end of 1st, and 3rd week post-treatment for immunological studies. The Leukogram in E. coli treated group was insignificant compared with the control group while lymphocytosis was clear compared with the infected group. Total protein, albumin, α-globulin and β-globulin were insignificantly

Share and Cite:

M. El-Boshy, O. Abdalla and A. Hassan, "Studies on the Immunomodulatory Effects of Lactoferrin in Rats Infected with E. coli," Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol. 2 No. 4, 2013, pp. 39-43. doi: 10.4236/jibtva.2013.24005.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. Mark, C. Annette and B. Jean, “Estimated Annual Costs Due to Selected Food-Borne Pathogens,” Data from the Centers for Disease Control and Prevention, Food- Related Illness and Death in the United States Economic Research Service, US Department of Agriculture, 2001.
[2] K. Shin, K. Yamauchi, S. Teraguchi, H. Hayasawa, M. Tomita, Y. Otsuka and S. Yamazaki, “Antibacterial Activity of Bovine Lactoferrin and Its Peptides against Enterohaemorrhagic Escherichia coli O157:H7,” Letters in Applied Microbiology, Vol. 26, 1998, pp. 407-411.
[3] W. J. van der Velden, N. M. Blijlevens and J. P. Donnelly, “The Potential Role of Lactoferrin and Derivatives in the Management of Infectious and Inflammatory Complications of Hematology Patients Receiving a Hematopoietic Stem Cell Transplantation,” Transplant Infectious Disease, Vol. 10, No. 2, 2007, pp. 68-71.
[4] C. C. Rosario, A. C. Lopaz, I. G. Tellez, O. A. Navarro, R. C. Anderson and C.C. Eslava, “Serotyping and Virulence Genes Detection in Escherichia coli Isolated from Fertile and Infertile Eggs, Dead-in-Shell Embryos, and Chickens with Yolk Sac Infection,” Avian Diseases, Vol. 48, No. 4, 2004, pp. 791-802.
[5] R. R. Arnold, M. F. Cole and J. R. McGhee, “A Bactericidal Effect for Human Lactoferrin,” Science, Vol. 197, No. 4300, 1977, pp. 263-265.
[6] S. Teraguchi, K. Ozawa, S. Yasuda, K. Shin, Y. Fukuwatari and S. Shimamura, “The Bacteriostatic Effects of Orally Administered Bovine Lactoferrin on Intestinal Enterobacteriaceae of SPF Mice Fed Bovine Milk,” Bioscience, Biotechnology, and Biochemistry, Vol. 58, No. 3, 1994, pp. 482-487.
[7] T. Susumu, S. Kouichirou, O. Tomohiro, K. Michiko, K. Akira, M. Hirofumi, F. Yasuo and S. Seiichi, “Orally Administered Bovine Lactoferrin Inhibits Bacterial Translocation in Mice Fed Bovine Milk,” Applied and Environmental Microbiology, Vol. 61, No. 11, 1995, pp. 4131- 4134.
[8] E. Lynn, B. H. Ronaldo, F. Y. Freda, R. H. Denis, A. S. Robert and P. S. Michael, “Lactoferrin Protects Neonatal Rats from Gut-Related Systemic Infection,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, Vol. 281, No. 5, 2001, pp. 1140-1150.
[9] M. Zimecki, J. Mazurier, G. Spik and J. A. Kapp, “Human Lactoferrin Induces Phenotypic and Functional Changes in Murine Splenic B Cells,” Immunology, Vol. 86, No. 1, 1995, pp. 122-127.
[10] E. H. Coles, “Textbook of Veterinary Clinical Pathology,” 4th Edition, W. B. Saunders Co., Philadelphia, 1986.
[11] K. S. Latimer, E. A. Malaffey and K. W. Prasse, “Duncan & Prasse’s Veterinary Laboratory Medicine: Clinical Pathology,” 4th Edition, Iowa State Press, Iowa City, 2003.
[12] R. J. Henry, D. C. Cannon and J. W. Winkelman, “Clinical Chemistry: Principles and Techniques,” Harper and Row, Hagerstown, 1974.
[13] B. Beutler and A. Cerami, “Cachectin: More than Tumor Necrosis Factor,” The New England Journal of Medicine, Vol. 316, No. 7, 1987, pp. 379-385.
[14] D. Legrand “Lactoferrin, a Key Molecule in Immune and Inflammatory Processes,” Biochemistry and Cell Biology, Vol. 90, No. 3, 2012, pp. 252-268.
[15] H. Tanaka, N. Tanaba, M. Shoji, T. Katono, S. Sato, M. Motohashi and M. Maeno, “Nicotine and Lipopolysaccharide Stimulate the Formation of Osteoclast-Like Cells by Increasing Macrophage Colony-Stimulating Factor and Prostaglandin E2 Production by Osteoblasts,” Life Sciences, Vol. 78, No. 15, 2006, pp. 1733-1740.
[16] P. Visca, C. Dalmastri, D. Verzili, G. Antonini, E. Chiancone and P. Valenti, “Interaction of Lactoferrin with Escherichia coli Cells and Correlation with Antibacterial Activity,” Medical Microbiology and Immunology, Vol. 179, No. 6, 1990, pp. 323-333.
[17] A. H. Liliana, E. Inga, B. Lars, D. Gunnar, A. H. Lars and M. Inger, “Human Lactoferrin and Peptides Derived from a Surface-Exposed Helical Region Reduce Experimental Escherichia coli Urinary Tract Infection in Mice,” Infection and Immunity, Vol. 68, No. 10, 2000, pp. 5816-5823.
[18] T. Zagulski, Z. Jarzabek, A. Zagulska, M. Jaszczak, I. E. Kochanowska and M. Zimecki, “Lactoferrin Stimulates Killing and Clearance of Bacteria but Does Not Prevent Mortality of Diabetic Mice,” Archivum Immunologiae et Therapia Experimentalis, Vol. 49, No. 6, 2001, pp. 431- 438.
[19] A. D. Von, P. O. Hasselgren and J. E. Fischer, “Hepatic Protein Synthesis in a Modified Septic Rat Model,” Journal of Surgical Research, Vol. 48, No. 5, 1990, pp. 476- 480.
[20] M. Kinsbergen, R. M. Bruckmaier and J. W. Blum, “Metabolic, Endocrine and Haematological Responses to Intravenous E. coli Endotoxin Administration in 1-Week- Old Calves,” Zentralblatt fur Veterinarmedizin Reihe A, Vol. 41, No. 7, 1994, pp. 530-547.
[21] N. A. Andréa and G. G. Loreny, “Lactoferrin and Free Secretory Component of Human Milk Inhibit the Adhesion of Enteropathogenic Escherichia coli to HeLa Cells,” BMC Microbiology, Vol. 1, 2001, p. 25.
[22] J. Tanaka, T. Sato, R. T. Jones, B. F. Trump and R. A. Cowley, “The Pathophysiology of Septic Shock: Responses to Different Doses of Live Escherichia coli Injection in Rats,” Advance in Shock Reserch, Vol. 9, 1983, pp. 101-114.
[23] N. C. Jain, J. L. Vegad, A. B. Shrivastava, N. K. Jain, U. K. Garg and G. N. Kolte, “Haematological Changes in Buffalo Calves Inoculated with Escherichia coli Endotoxin and Corticosteroids,” Research in Veterinary Science, Vol. 47, No. 3, 1989, pp. 305-308.
[24] R. P. Richardson, C. D. Rhyne, Y. Fong, D. G. Hesse, K. J. Tracey, M. A. Marano, S. F. Lowry, A. C. Antonacci and S. E. Calvano, “Peripheral Blood Leukocyte Kinetics Following in Vivo Lipopolysaccharide (LPS) Administration to Normal Human Subjects. Influence of Elicited Hormones and Cytokines,” Annals of Surgery, Vol. 210, No. 2, 1989, pp. 239-245.
[25] J. Tong, H. Kishi, T. Matsuda and A. Muraguchi, “A Bone Marrow-Derived Stroma Cell Line, ST2, Can Support the Differentiation of Fetal Thymocytes from the CD4-CD8-Double Negative to the CD4+ CD8+ Double Positive Differentiation Stage in Vitro,” Immunology, Vol. 97, No. 4, 1999, pp. 672-678.
[26] B. Adamik, A. Wlaszczyk, M. Zimecki and A. Kübler, “Lactoferrin Effects on Immune Response in Critically Ill,” 17th International Symposium on Intensive Care and Emergency Medicine, Brussels, 18-21 March 1997.
[27] K. T. Jaya and P. K. Sahoo, “Dietary Bovine Lactoferrin Induces Changes in Immunity Level and Disease Resistance in Asian Catfish Clarias Batrachus,” Veterinary Immunology and Immune Pathology, Vol. 94, No. 1-2, 2003, pp. 1-9.
[28] P. M. Joseph, R. S. Matt and M. D. Claire, “Early Response Cytokines and Innate Immunity: Essential Roles for TNF Receptor 1 and Type I IL-1 Receptor during Escherichia coli Pneumonia in Mice,” The Journal of Immunology, Vol. 166, No. 6, 2001, pp. 4042-4048.
[29] J. S. Theodore, “Anti-Inflammatory Cytokines and Cytokine Antagonists,” Current Pharmaceutical Design, Vol. 6, No. 6, 2000, pp. 633-649.
[30] M. Zimecki, J. Artym, G. Chodaczek, M. Kocieba and M. L. Kruzel, “Protective Effects of Lactoferrin in Escherichia coli-Induced Bacteremia in Mice: Relationship to Reduced Serum TNF Alpha Level and Increased Turnover of Neutrophils,” Inflammation Research, Vol. 53, No. 7, 2004, pp. 292-296.
[31] B. Adamik and A. Wlaszczyk, “Lactoferrin—Its Role in Defense against Infection and Immune Tropic Properties,” Postepy Higieny i Medycyny Doswiadczalnej, Vol. 50, No. 1, 1996, pp. 33-41.
[32] P. A. Spagnuolo, R. P. Bird and L. Hoffman-Goetz, “Effect of Short-Term Dietary Intake of Bovine Lactoferrin on Intestinal Lymphocyte Apoptosis in Healthy Mice,” Nutrition, Vol. 23, No. 11-12, 2007, pp. 812-817.
[33] S. P. Crouch, K. J. Slater and J. Fletcher, “Cytokine Release from Mononuclear Cells by the Iron-Binding Protein Lactoferrin,” Blood, Vol. 80, No. 1, 1992, pp. 235- 240.
[34] W. H. Teraguchi, H. Kuwata, K. Yamauchi and Y. Tamura, “Protection against Infections by Oral Lactoferrin: Evaluation in Animal Models,” BioMetals, Vol. 17, No. 3, 2004, pp. 231-234.
[35] K. Yamauchi, T. Toida, S. Nishimura, E. Nagano, O. Kusuoka, S. Teraguchi, H. Hayasawa, S. Shimamura and M. Tomita, “13-Week Oral Repeated Administration Toxicity Study of Bovine Lactoferrin in Rats,” Food and Chemical Toxicology, Vol. 38, No. 6, 2000, pp. 503-512.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.